Article | September 4, 2018

Industrializing Cell Therapy

Source: GE Healthcare Life Sciences
Cell

Insights on cell therapy manufacturing challenges and how to overcome them.

Many see the growth of the cell and gene therapy field as the culmination of a healthcare revolution – a move away from one-size-fits-all approaches to truly individualized and personalized treatments. Over the past few decades, increased understanding of immunology and genomics has generated an unprecedented amount of biological information, which scientists are now beginning to translate into a new caliber of medicine. It is an especially exciting time for the field; the first two approved CAR-T therapies are already treating patients in the US and Europe.

“The complete response rates being seen for these kind of therapies are inspiring,” explains Madhusudan Peshwa, Ph.D., Chief Technology Officer, Cell Therapy business, at GE Healthcare. “I am not aware of any small molecule drug or any biological drug having the ability to deliver such phenomenal outcomes for patients. This is stimulating the growth of the cell and gene therapy industry.”